Alpha Cognition (ACOG) Registration Filing summary

Company overview and business model

• Focuses on developing treatments for neurodegenerative diseases, notably Alzheimer's, with lead product ZUNVEYL targeting long-term care and nursing homes specializing in Alzheimer's disease.

• ZUNVEYL launched commercially in March 2024, priced at $749/month, and is positioned as a next-generation acetylcholinesterase inhibitor with minimal gastrointestinal side effects.

• Pipeline includes pre-clinical programs for ZUNVEYL in combination with memantine, ALPHA-1062 (sublingual and intranasal), and Progranulin GEMs for ALS and SMA, with some assets intended for out-licensing.

• Entered an exclusive licensing agreement with China Medical System Holdings for ZUNVEYL in Asia-Pacific (excluding Japan), Australia, and New Zealand, with $44 million in total deal value and royalties on net sales.

Financial performance and metrics

• Reported $2.93 million in revenue for Q1 2025, with a net loss of $2.01 million for the same period.

• Fiscal year 2024 revenue was $6.62 million, with a net loss of $14.64 million; cash and cash equivalents stood at $45.53 million as of March 31, 2025.

• Weighted average shares outstanding increased to 16,019,787 as of March 31, 2025.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive proceeds from warrant exercises if not cashless.

• Proceeds from prior private placements and public offerings have supported commercial launch, R&D, and operational expansion.